RVPH 250117 1.00C (RVPH250117C1000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

RVPH250117C1000

Watchlist

1.10
+0.05+4.76%

15min DelayTrading Jan 7 14:00 ET

1.10High1.10Low

Intraday

5D
Daily

News

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit
Reviva PharmaceuticalsJan 7 00:00 ET
Express News | Applied Therapeutics Inc - Shoshana Shendelman Steps Down as CEO
ReutersDec 20, 2024 07:02 ET
Express News | Applied Therapeutics Appoints John H. Johnson as Executive Chairman
ReutersDec 20, 2024 07:00 ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
BenzingaDec 17, 2024 16:05 ET
Sector Update: Health Care Stocks Ease Late Afternoon
MT NewswiresDec 17, 2024 15:56 ET
Top Midday Decliners
MT NewswiresDec 17, 2024 14:29 ET

Comments

iDontKnowHowToTrade

Jan 2 09:23

$Reviva Pharmaceuticals (RVPH.US)$ LET IT FLYYY

Trytosaveabit

Dec 16, 2024 16:25

Of course! Hehehe

$Reviva Pharmaceuticals (RVPH.US)$ Reviva Announces Proposed Public Offering
GlobeNewswire· 6 mins ago

Jaguar8

Dec 16, 2024 07:00

NEWS

$Reviva Pharmaceuticals (RVPH.US)$
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
Monday, 16th December at 8:00 am
– Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year –
– Generally well-tolerated with low rates of adverse events and discontinuation –
– Full data set from open-label extension (OLE) of R...

Jaguar8

Dec 15, 2024 20:58

🔶December 2024 Upcoming Catalysts. Save it. In alphabetical order

$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...

72641842

Dec 12, 2024 13:25

$Reviva Pharmaceuticals (RVPH.US)$Analysts Think This $3 Stock Has 430% Upside Potential - Trades Of The Day